GlaxoSmithKline (LON:GSK) Earns “Hold” Rating from Shore Capital

Share on StockTwits

GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating reissued by equities research analysts at Shore Capital in a report released on Thursday, ThisIsMoney.Co.Uk reports.

A number of other research analysts also recently issued reports on the stock. UBS Group reissued a “buy” rating and set a GBX 1,900 ($24.99) price objective on shares of GlaxoSmithKline in a research report on Monday, December 2nd. DZ Bank boosted their price objective on shares of GlaxoSmithKline from GBX 1,850 ($24.34) to GBX 2,000 ($26.31) and gave the company a “buy” rating in a research report on Thursday, October 31st. HSBC set a GBX 2,110 ($27.76) price objective on shares of GlaxoSmithKline and gave the company a “buy” rating in a research report on Wednesday, December 18th. Jefferies Financial Group boosted their price objective on shares of GlaxoSmithKline from GBX 1,850 ($24.34) to GBX 2,000 ($26.31) and gave the company a “buy” rating in a research report on Tuesday, December 17th. Finally, Liberum Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline in a research report on Friday, November 15th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of GBX 1,876.47 ($24.68).

Shares of GlaxoSmithKline stock opened at GBX 1,846 ($24.28) on Thursday. The company has a current ratio of 0.82, a quick ratio of 0.50 and a debt-to-equity ratio of 183.00. The company’s fifty day simple moving average is GBX 1,776.73 and its two-hundred day simple moving average is GBX 1,705.67. The company has a market cap of $92.11 billion and a P/E ratio of 20.22. GlaxoSmithKline has a 12-month low of GBX 1,429.80 ($18.81) and a 12-month high of GBX 1,851.15 ($24.35).

In other GlaxoSmithKline news, insider Vivienne Cox bought 308 shares of GlaxoSmithKline stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average cost of GBX 1,725 ($22.69) per share, with a total value of £5,313 ($6,988.95). Insiders bought a total of 330 shares of company stock worth $569,837 over the last ninety days.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Story: Percentage Gainers

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Set Altair Engineering Inc  Price Target at $35.20
Analysts Set Altair Engineering Inc Price Target at $35.20
Brokerages Set Godaddy Inc  Price Target at $89.00
Brokerages Set Godaddy Inc Price Target at $89.00
Zacks: Brokerages Expect Alteryx Inc  to Announce -$0.08 EPS
Zacks: Brokerages Expect Alteryx Inc to Announce -$0.08 EPS
Bitradio  Tops One Day Trading Volume of $4.00
Bitradio Tops One Day Trading Volume of $4.00
Comparing Coupa Software  & Upland Software
Comparing Coupa Software & Upland Software
Critical Comparison: FFW  and Central Federal
Critical Comparison: FFW and Central Federal


 
© 2006-2020 Zolmax.